Beyond Air (NASDAQ:XAIR) reported Q1 fiscal 2026 results, with a 157% increase in GAAP revenue to $1.8 million, falling short of analyst estimates. Earnings per share improved to $(1.53), beating the prior-year quarter but missing consensus by 59.4%. The quarter saw international sales for the first time, expanded U.S. hospital placements, and cost reductions. Operating expenses decreased, but the net loss remained sizable. The company submitted a PMA supplement for a new device to the FDA and made progress in its pipeline. Cash burn remains a concern, with a cash position of $6.5 million and a focus on regulatory approvals and international growth.

Key highlights for Beyond Air in Q1 fiscal 2026 included significant GAAP revenue growth, expansions in the U.S. hospital count, and the first international sales of its products. The company achieved distribution deals in multiple countries and reduced operating expenses compared to the prior year. Despite positive gross profit, the net loss remained significant, highlighting the need to balance expenses with revenue growth. Regulatory progress was made with the submission of a PMA supplement for a new device, and the company is focused on achieving sustained double-digit revenue growth and controlling operating expenses for the full fiscal year.

Looking ahead, Beyond Air reiterated its full-year revenue guidance of $12 million to $16 million for fiscal 2026. The company aims to support sustained revenue growth and increase efficiency in operating expenses. Investors should monitor key regulatory approvals, international distribution agreements, and cost control measures to assess the company’s performance through the remainder of the fiscal year. Cash burn remains a critical concern, and achieving revenue targets will be essential for financial stability and growth.

Read more at Nasdaq: Beyond Air Sales Jump 158 Percent